Lexicon Pharmaceuticals Inc (LXRX) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Lexicon Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Lexicon Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Lexicon Pharmaceuticals Inc recorded a cumulative net loss of $-61 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -27.05%.
However, within the Healthcare sector 401 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3262, from total ROA ranking in the first quarter of 2026 at 4102.
Lexicon Pharmaceuticals Advances Toward Sotagliflozin Resubmission with Additional Data Submission to the FDA Lexicon Pharmaceuticals announced a significant update regarding its efforts to advance the approval of Zynquista (sotagliflozin) for the treatment of Type 1 Diabetes (T1D). The company has submitted additional data to the U.S. Food and Drug Administration (FDA) with the aim of bolstering the benefit-risk profile of Zynquista, addressing concerns raised in a Complete Response Letter (CRL) from December 2024. This move is part of Lexicon s strategic plan to ensure a robust resubmission of the New Drug Application (NDA) for sotagliflozin as an adjunct to insulin therapy.The fresh data sent to the FDA encompasses findings from ongoing, third-party funded, investigator-sponsored trials. These supplementary insights are intended to comprehensively address the issues highlighted in the previous CRL, marking a critical step in the drug s regulatory journey. The company hopes that these efforts will underscore the potential of sotagliflozin to enhance glycemic control in patients with T1D, especially those also suffering from chronic kidney disease.
Lexicon Pharmaceuticals Faces Financial Headwinds Amid FDA Advisory Approval for Zynquista Amid a backdrop of significant financial challenges, Lexicon Pharmaceuticals Inc. recently announced the outcome of an FDA Advisory Committee meeting concerning Zynquista (sotagliflozin), as an adjunct to insulin therapy for managing glycemic control in adults with Type 1 diabetes and chronic kidney disease. The PDUFA (Prescription Drug User Fee Act) target action date for the drug has been set for December 20, 2024, injecting a glimmer of hope into the beleaguered company’s prospects. Despite the favorable advisory committee outcome, Lexicon’s struggles are starkly evident in its financial reports. The company recorded a cumulative net loss of $202 million over the 12 months ending in the second quarter of 2024, resulting in a troubling return on assets (ROA) of -62.36%. This decline is alarming, particularly when contextualized against the performance of 651 other companies in the same healthcare sector, which reported higher returns on assets. While Lexicon s overall ROA ranking has improved—from 4032 in Q1 2024 to 3929—this marginal advancement does little to mask the severity of its financial troubles.The company’s challenges are underscored by upcoming medical conferences where Lexicon intends to showcase innovative trial designs and insights into its clinical studies. The SONATA-HCM trial, focused on the effects of sotagliflozin in patients suffering from Hypertrophic Cardiomyopathy (HCM), represents a pivotal point for Lexicon as it taps into an underserved patient demographic. Current patient randomization efforts for the SONATA-HCM clinical trial signal ongoing dedication to advancing the therapeutic potential of its flagship compound, sotagliflozin, which acts as a dual SGLT1 and SGLT2 inhibitor.
Innovative Sotagliflozin Trial Designs and New Insights to be Unveiled by Lexicon Pharmaceuticals at Upcoming Medical Conferences Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is poised to showcase groundbreaking designs and new insights in its ongoing clinical trials for sotagliflozin, a novel dual SGLT1 and SGLT2 inhibitor, across several major medical events.In the highly anticipated SONATA-HCM (Study of OTAGLOFLOZIN in NAïve T2D and their Association with Hypertrophic Cardiomyopathy) trial, the company will present the design of its Phase 3 study targeting Hypertrophic Cardiomyopathy (HCM) at an upcoming medical congress. This study marks a pivotal step for Lexicon as it explores the therapeutic potential of sotagliflozin in an underserved and progressively growing patient population suffering from HCM. Patient randomization for the SONATA-HCM clinical trial is currently underway, underscoring the trial s advancement towards crucial endpoints.
Unlocking New Potential: The Impact of Sotagliflozin on Diabetes Management In recent developments within diabetes pharmacotherapy, new secondary analyses stemming from Phase 3 clinical trials have showcased the potential of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, in enhancing glucose control among patients with basal insulin-treated Type 2 diabetes. The findings are especially significant given the backdrop of positive results related to its use in Type 1 diabetes, which advocates for its broader applications in complex diabetes management. Key Findings from Phase 3 TrialsThe secondary analysis revealed that patients receiving sotagliflozin displayed notable improvements in several critical metrics of glycemic control. Most importantly, the study highlighted enhanced Time-In-Range (TIR), which refers to the duration that glucose levels remain within a target range. Maintaining optimal TIR is paramount in managing diabetes, as it has been linked to reduced risk of complications and improved overall health outcomes. Additionally, the analysis demonstrated that treatment with sotagliflozin resulted in favorable changes in glucose variability and other key parameters related to glucose metabolism. These improvements are essential, not only for achieving immediate glycemic targets but also for long-term management strategies in diabetes care, which often involve complex medication regimens and patient adherence challenges.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
